5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Original reporting
Published Sep 8, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 7:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$BJDX
Bullish
high confidence
Mentioned
$BJDX · $PHVS · $ROIV · $ATRA · $PDSB
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BJDXBullishMed
01

Why it matters

These events collectively suggest a short‑term bullish bias for the named tickers, though long‑term outcomes depend on regulatory approvals and trial progress.

02

Market read

Each company's news is a primary disclosure with material impact, making the article highly relevant for traders tracking biotech catalysts.

03

What to watch

Potential competition in HAE and PH‑ILD spaces could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

The article highlights recent corporate developments for five biotech companies, including trial results, a federal partnership, and a financing round.

Company-level read

Ticker impact

$BJDXBullishHigh confidence
Context

Bluejay Diagnostics announced a federal partnership with Lovell Government Services to distribute its Symphony System for sepsis triage.

Expected impact

short-term upside as investors price the partnership.

Evidence & confidence

Exclusive distributor role in VA, DoD, and other federal channels expands market reach.

$PHVSBullishHigh confidence
Context

Pharvaris reported positive Phase 3 topline results for Deucrictibant XR, showing an 83% reduction in HAE attack rate.

Expected impact

mid-term rally ahead of FDA submission.

Evidence & confidence

Phase 3 success is material for valuation and regulatory timeline.

$ROIVBullishHigh confidence
Context

Roivant disclosed positive Phase 2 PHocus trial results for mosliciguat in PH‑ILD, with a 56.3% reduction in pulmonary vascular resistance.

Expected impact

moderate upside as investors anticipate Phase 3 enrollment.

Evidence & confidence

Phase 2 efficacy signals are material for a biotech pipeline.

$ATRANeutralMedium confidence
Context

Atara Biotherapeutics updated on the anticipated resubmission of its tabelecleucel BLA with additional data from the Phase 3 ALLELE study.

Expected impact

limited short‑term move; focus on later quarter.

Evidence & confidence

Resubmission indicates ongoing regulatory risk but no immediate catalyst.

$PDSBBullishHigh confidence
Context

PDS Biotech announced up to $22.55 million PIPE financing led by Nant Capital to fund its PDS0301 oncology program.

Expected impact

short‑term boost as financing news is priced in.

Evidence & confidence

Substantial raise for a micro‑cap biotech is material for liquidity and pipeline progress.

Market effects

Positive clinical data across multiple biotech firms may lift sector sentiment.

U.S. biotech market gains from federal partnership and financing news.

Limited to U.S. and investors focused on biotech pipelines.

Counterpoint

Some investors may wait for FDA approval milestones before committing, given early‑stage data risk.

Key entities

  • Bluejay Diagnostics

    Biotech diagnostics firm

  • Pharvaris

    Biopharma developing HAE therapy

  • Roivant

    Biotech platform company

  • Atara Biotherapeutics

    Cell therapy developer

  • PDS Biotech

    Oncology-focused biotech

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$PDSBMed

PDS Biotech Reports Third Quarter 2026 Financial Results

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., November 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.